

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Otsuka Pharmaceutical Co. Ltd	11/05/2010
RECEIVING PARTY DATA	
Name:	MethylGene Inc.
Street Address:	7220 Frederick-Banting
City:	Montreal
State/Country:	CANADA
Postal Code:	H4S 2A1
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12920676
CORRESPONDENCE DATA	
Fax Number:	(312)876-2020
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	rburke@woodphillips.com
Correspondent Name:	Joseph C. Zuccherro
Address Line 1:	Wood, Phillips, Katz, Clark & Mortimer
Address Line 2:	500 W. Madison Street - Suite 3800
Address Line 4:	Chicago, ILLINOIS 60661
ATTORNEY DOCKET NUMBER:	MET10638P00041US
NAME OF SUBMITTER:	Joseph C. Zuccherro
Total Attachments: 3 source=OtsukaMet#page1.tif source=OtsukaMet#page2.tif source=OtsukaMet#page3.tif	

CH \$40.00 12920676

501370928

PATENT
REEL: 025461 FRAME: 0472

ASSIGNMENT

WHEREAS, Otsuka Pharmaceutical Co. Ltd., a corporation organized and existing under the laws of Japan, having a place of business at 2-9 Kanada-Tsukasamachi, Chiyodaku Tokyo, 101-8535, Japan hereinafter called the "Assignor" have made the invention described in the United States patent application entitled "Inhibitors of VEGF Receptor and HGF Receptor Signaling" that has a U.S. Patent Application Serial Number of 12/920,676 and was filed on _____;

WHEREAS, MethylGene Inc., a corporation organized and existing under the laws of Canada, having a place of business at 7220 Frederick-Banting, Montreal, Quebec, H4S 2A1, Canada, hereinafter called the "Assignee", desires to acquire the entire right, title and interest in and to the invention and to the patent application identified above, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below.

NOW THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignors have sold, assigned and transferred, and by these presents do sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States and elsewhere; together with the entire right, title and interest in and to said invention and all patent applications, patents, utility models and designs therefore in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications, patents, utility models and designs defined above; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignors hereby covenant and agree, for both the Assignors and Assignors' legal representative, that Assignors have the full right to convey the interest assigned by this Assignment; and that the Assignors will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of the Assignment; and that the Assignors will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Agreement.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, THE Assignors have executed this agreement.

MET10638P00041US

DATED: Nov. 5, 2010

Seiji Ejima
Otsuka Pharmaceutical Co. Ltd.
Seiji Ejima
Intellectual Property Department Director:

Then personally appeared before me this 5th day of November, 2010, the above named Seiji Ejima who acknowledged the execution of the foregoing instrument to be his free act and deed.

K. Nomura
Witness

DATED: Nov 27, 2010

Charles Grubszajn
MethylGene Inc.
Charles Grubszajn
President and Chief Executive Officer

Then personally appeared before me this 27th day of November, 2010, the above named Charles Grubszajn who acknowledged the execution of the foregoing instrument to be his free act and deed.

Terry Macgregor
Commissioner for Oaths



WITNESSES (NAME ADDRESS)

KEISUKE NOMURA

5 9 7 - 1 UO-MACHI, TAKASAGO-CHO, TAKASAGO-SHI, HYOGO, JAPAN